Shared on20 Sep 25Fair value Decreased 80%
Despite no material change in either future P/E or net profit margin, the consensus analyst price target for Zydus Wellness has sharply decreased from ₹2447 to ₹489.43. What's in the News Incorporated wholly owned subsidiary Alidac UK Limited in the United Kingdom.
Shared on05 Sep 25Fair value Increased 2.69%
The upward revision in Zydus Wellness's price target reflects a slight increase in its future P/E multiple while profitability remains stable, resulting in a new consensus fair value of ₹2,447. What's in the News Incorporated a wholly owned subsidiary, Alidac UK Limited, in the United Kingdom.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 4.60%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 2.52%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on13 Mar 25Fair value Decreased 2.10%
AnalystConsensusTarget has decreased future PE multiple from 43.1x to 36.5x.